MYOSLID: A Potential Drug Target for Cardiovascular Diseases (G105373853)

Target Name: MYOSLID

NCBI ID: G105373853

MYOSLID

Other Name(s): Myocardin-induced smooth muscle lncRNA, inducer of differentiation | myocardin-induced smooth muscle lncRNA, inducer of differentiation

MYOSLID: A Potential Drug Target for Cardiovascular Diseases

Myocardin-induced smooth muscle lncRNA (MYOSLID) is a non-coding RNA that has been identified as a potential drug target or biomarker for various cardiovascular diseases, including heart failure, hypertension, and myocardial infarction. The myocardium is the heart muscle that pumps blood throughout the body, and smooth muscle is the muscle that contracts and relaxes to regulate blood flow. Therefore, any RNA molecule that can modulate the myocardial contractile function could be a promising target for cardiovascular drugs.

MYOSLID is a non-coding RNA molecule that is expressed in the myocardium and has been shown to play a role in the regulation of myocardial contractile function. It is composed of 299 amino acid residues and has a molecular weight of 31.1 kDa. It is located in the cytoplasm and has been shown to interact with various cellular structures, including the endoplasmic reticulum, the transmembrane protein ZDH123, and the myosin ATPase.

MYOSLID has been shown to regulate various myocardial functions, including contractile force, heart rate, and cardiac output. It has also been shown to play a role in the regulation of cellular processes, including cell cycle progression, apoptosis, and autophagy. In addition, MYOSLID has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

MYOSLID has been shown to be a promising drug target or biomarker for various cardiovascular diseases because of its involvement in the regulation of myocardial function. It has been shown to be involved in the development of cardiomyopathy, which is a progressive disease characterized by the thickening of the heart muscle and decreased contractive function. Cardiomyopathy can be caused by a variety of factors, including genetic, environmental, and metabolic conditions.

MYOSLID has also been shown to be involved in the regulation of hypertension, which is a common cardiovascular disease that can lead to a variety of complications, including heart failure, stroke, and heart attacks. Hypertension is characterized by an increase in blood pressure, and it can be caused by a variety of factors, including genetic, environmental, and metabolic conditions.

MYOSLID has also been shown to be involved in the regulation of myocardial infarction, which is a common cardiovascular disease that occurs when the blood flow to the heart is blocked, resulting in damage to the heart muscle. Myocardial infarction can be caused by a variety of factors, including blood clots, physical exertion, and emotional stress.

In conclusion, MYOSLID is a non-coding RNA molecule that is expressed in the myocardium and has been shown to play a role in the regulation of myocardial contractile function. It is a promising drug target or biomarker for various cardiovascular diseases because of its involvement in the regulation of myocardial function. Further research is needed to fully understand the role of MYOSLID in the regulation of cardiovascular disease.

Protein Name: Myocardin-induced Smooth Muscle LncRNA, Inducer Of Differentiation

The "MYOSLID Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYOSLID comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets